TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01579279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652 6 mg
Description: 6 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652 12 mg
Description: 12 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652 12 mg - 18 mg
Description: 12 mg - 18 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT01409668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. Fermentum
Description: L. Fermentum
Study: NCT01579279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine capsules
Study: NCT04135768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wrist joint haematoma washout
Description: After plating of the distal radius is performed, a small incision is made on the wrist joint capsule. This is the portal for fluid efflux. An intravenous cannula is used to puncture the wrist joint capsule adjacent to the first incision and normal saline is infused through this cannula into the wrist joint. The infusion continues until the fluid efflux from the first portal is clear and no longer blood stained. This will be the point at which the washout is considered to be complete.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Volar locking plate insertion of the distal radius
Description: An anatomical locking plate is applied to the distal radius fracture using screws
Study: NCT00639184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intervention counseling
Description: Bi-monthly home visits by counselor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education counseling
Description: World Health Education health education counseling program at home visits,twice per month
Study: NCT04156698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Study: NCT04135768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar locking plate insertion of the distal radius
Description: An anatomical locking plate is applied to the distal radius fracture using screws
Study: NCT01983254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coping skills training
Description: 6-session coping skills training program delivered by telephone w/ web augmentation
Study: NCT04562376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Description: The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
Study: NCT01983254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education program
Description: web-based, ICU-specific education program
Study: NCT00697697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.135mg MAP0010
Description: 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Study: NCT04562376

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency of high-intensity resistance training
Description: The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
Study: NCT04184141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine Hydrochloride
Description: Hyroxyzine hydrochloride is given to the patient one hour before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam tablet
Description: Alprozolam is given to the patient one hour before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo candy
Study: NCT01101178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 80-mg tablet x 1 dose taken with food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
Study: NCT00522834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elesclomol (STA-4783)
Description: 213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
Study: NCT02726620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoproterenol
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT00522834

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
Study: NCT02608619

Intervention type: RADIATION
Intervention: F-choline PET Scan

Intervention type: DEVICE
Intervention: FDG-PET
Study: NCT00697697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg MAP0010
Description: 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
Study: NCT02608619

Intervention type: PROCEDURE
Intervention: biopsy
Study: NCT02726620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Cardiovascular drugs used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Cardiovascular drugs used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT00858988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 100mg of rifaxin for 7 consecutive days, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 7 consecutive days
Study: NCT02726620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch solutions
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch solutions
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT02251847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin/Ezetimibe
Description: Rosuvastatin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Ezetimibe
Description: Rosuvastatin 5mg
Study: NCT02726620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cells
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Packed Red Blood Cells
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solutions
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin solutions
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-Lyte
Description: Intravenous fluid used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02251847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin/Ezetimibe
Description: Rosuvastatin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Ezetimibe
Description: Rosuvastatin 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin/Ezetimibe
Description: Rosuvastatin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Ezetimibe
Description: Rosuvastatin 5mg
Study: NCT02726620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroprocaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Local anesthetic used for central neuraxial anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT01367041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vibration
Description: Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vibration
Description: Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
Study: NCT02515929

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligomeric Proanthocyanidins

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06144879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double rods without dual-headed screw
Description: adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with traditional double rods (No dual-headed screw used)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three rods with one dual-headed screw
Description: adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with three rods (one dual-headed screw used in unilateral side)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: four rods with two dual-headed screw
Description: adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with four rods (two dual-headed screw used in bilateral side)
Study: NCT03159559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo-PGE1
Description: Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
Study: NCT03395899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PD-L1 antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Highly selective small-molecule inhibitor of MEK1 and MEK2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Highly specific humanized monoclonal antibody that targets VEGF
Study: NCT03688815

Intervention type: DIAGNOSTIC_TEST
Intervention: myocardial perfusion scintigraphy
Description: Myocardial perfusion scintigraphy as it is described in the international literature.
Study: NCT02986126

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resiliency Class
Description: See Arm Description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resource for Services (RS)
Description: See Resource for Services (RS) Description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resource for Services (RS)
Description: See Resource for Services (RS) Description
Study: NCT02528825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil titration
Description: Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
Study: NCT02096016

Intervention type: PROCEDURE
Intervention: Human Papilloma Virus test from the vaginal vault
Description: Surveillance after surgical treatment of early stage cervical cancer
Study: NCT01685775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal/transumbilical

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needlescopic with 3 trocars
Study: NCT06375070

Intervention type: PROCEDURE
Intervention: PFO closure
Description: PFO closure

Intervention type: PROCEDURE
Intervention: PFO closure
Description: PFO closure

Intervention type: PROCEDURE
Intervention: PFO closure
Description: PFO closure

Intervention type: DRUG
Intervention: anticoagulant
Description: rivaroxaban

Intervention type: DRUG
Intervention: anticoagulant
Description: rivaroxaban

Intervention type: DRUG
Intervention: anticoagulant
Description: rivaroxaban
Study: NCT02956343

Intervention type: DEVICE
Intervention: Five minutes pulse wave recording
Description: Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
Study: NCT00933153

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus
Description: Ensure plus supplement with meals

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meals on Wheels
Description: Two Meals on Wheels twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meals on Wheels
Description: Two Meals on Wheels twice daily
Study: NCT02839317

Intervention type: BIOLOGICAL
Intervention: Biological
Description: comparison of microbiota, genetic profile between pediatric- and elderly-onset CD

Intervention type: BIOLOGICAL
Intervention: Biological
Description: comparison of microbiota, genetic profile between pediatric- and elderly-onset CD

Intervention type: BIOLOGICAL
Intervention: Biological
Description: comparison of microbiota, genetic profile between pediatric- and elderly-onset CD

Intervention type: BIOLOGICAL
Intervention: Biological
Description: comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
Study: NCT03733236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ISS Active Stimulation
Description: ISS SPG stimulation and standard of care
Study: NCT04341090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
Study: NCT02654301

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test 1
Description: sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test 2
Description: sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test 3
Description: sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: sucrose 50 g + deionized water 100 g
Study: NCT04341090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
Study: NCT04337788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth applications
Description: telehealth applications during 30 days/patient
Study: NCT01937299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
Study: NCT01879059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: short period of inactivity (5 days) followed by a return to physical activity (1 day)
Study: NCT00481624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa plus Iron
Description: 1. One (1) injection of Procrit®, by needle, inserted just under the skin;~2. 125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.~These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.~In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan.
Study: NCT03114787

Intervention type: OTHER
Group type: OTHER
Intervention: Study on patients with respiratory resuscitation
Description: Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult

Intervention type: OTHER
Group type: OTHER
Intervention: Study on patients with respiratory resuscitation
Description: Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult